Browse By

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) reported earnings of $0.09 per share beating Walls Streets expectations.

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) reported Q1 2017 earnings this Afternoon, coming in at $0.09 per share, beating Wall Street’s estimates of $0.07 per Share. Revenue for the quarter came in at $56.67 million missing the streets estimates of $63.74 million

Analyst Coverage For Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)
These are 1 Hold Rating, 5 Buy Ratings .
The current consensus rating for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) is Buy (Score: 2.83) with a consensus target price of $20.33 , a potential (36.47% upside)Recent Insider Trading for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)

  • On 1/3/2017 Floyd F Petersen, Director, sold 400 with an average share price of $18.61 per share and the total transaction amounting to $7,444.00.
  • On 12/15/2016 Diane G Gerst, EVP, sold 2,940 with an average share price of $20.51 per share and the total transaction amounting to $60,299.40.
  • On 12/5/2016 Rong Zhou, EVP, sold 61 with an average share price of $20.70 per share and the total transaction amounting to $1,262.70.
  • On 12/1/2016 Floyd F Petersen, Director, sold 400 with an average share price of $20.26 per share and the total transaction amounting to $8,104.00.
  • On 11/28/2016 Jason B Shandell, Insider, sold 26,335 with an average share price of $20.48 per share and the total transaction amounting to $539,340.80.
  • On 11/15/2016 Howard Lee, Director, sold 37,994 with an average share price of $20.65 per share and the total transaction amounting to $784,576.10.

About Company Amphastar Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable, inhalation and intranasal products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products. The finished pharmaceutical products segment manufactures, markets and distributes enoxaparin, Cortrosyn, Amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The API segment manufactures and distributes recombinant human insulin and porcine insulin. The Company also manufactures and sells insulin API. As of December 31, 2016, the Company manufactured and sold 19 products. As of December 31, 2016, the Company developed a portfolio of 15 generic abbreviated new drug applications (ANDAs) three generic biosimilar product candidates and six injectable and inhalation product candidates. Recent Trading for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) Shares of Amphastar Pharmaceuticals Inc closed the previous trading session at 14.94 down -0.06 -0.40% with 310,489 shares trading hands.

The post Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) reported earnings of $0.09 per share beating Walls Streets expectations. appeared first on Market Exclusive.

Leave a Reply

Your email address will not be published. Required fields are marked *